Conatus Pharmaceuticals (CNAT) Given “Buy” Rating at Oppenheimer
Other equities research analysts have also recently issued research reports about the company. S&P Equity Research raised their target price on Conatus Pharmaceuticals from $5.02 to $5.69 in a research note on Wednesday, January 24th. Roth Capital initiated coverage on Conatus Pharmaceuticals in a research note on Thursday, February 8th. They set a buy rating and a $20.00 target price for the company. HC Wainwright reaffirmed a buy rating and set a $17.00 target price on shares of Conatus Pharmaceuticals in a research note on Thursday, March 8th. ValuEngine upgraded Conatus Pharmaceuticals from a sell rating to a hold rating in a report on Friday, March 2nd. Finally, Zacks Investment Research upgraded Conatus Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. Conatus Pharmaceuticals presently has an average rating of Buy and a consensus target price of $13.67.
Conatus Pharmaceuticals stock traded down $0.06 during midday trading on Thursday, reaching $6.25. The company had a trading volume of 200,727 shares, compared to its average volume of 600,704. Conatus Pharmaceuticals has a fifty-two week low of $3.88 and a fifty-two week high of $9.40. The firm has a market capitalization of $193.29, a PE ratio of -10.32 and a beta of 1.28. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 0.47.
A number of large investors have recently made changes to their positions in the business. New York State Common Retirement Fund boosted its holdings in Conatus Pharmaceuticals by 156.4% in the third quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 14,700 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Conatus Pharmaceuticals by 77.4% in the fourth quarter. Wells Fargo & Company MN now owns 34,036 shares of the biotechnology company’s stock worth $157,000 after acquiring an additional 14,848 shares in the last quarter. Voya Investment Management LLC bought a new position in Conatus Pharmaceuticals in the second quarter worth approximately $101,000. Stone Ridge Asset Management LLC bought a new position in shares of Conatus Pharmaceuticals in the fourth quarter valued at approximately $143,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Conatus Pharmaceuticals by 17.3% in the fourth quarter. Bank of New York Mellon Corp now owns 215,843 shares of the biotechnology company’s stock valued at $997,000 after purchasing an additional 31,822 shares in the last quarter. Institutional investors and hedge funds own 39.49% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Conatus Pharmaceuticals (CNAT) Given “Buy” Rating at Oppenheimer” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/conatus-pharmaceuticals-cnat-given-buy-rating-at-oppenheimer/1960647.html.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.